TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21332551

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg every 12 h)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (2.0 g per day for 7 days)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intestinal permeability index (IPI) measured the day after admission
Number of subjects: 113
Study: 19857627

Group type: EXPERIMENTAL
Intervention: Low-energy-density yogurt with inulin (6 g)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-energy-density yogurt (440 kcal; 0.9 kcal/g)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-energy-density yogurt (180 kcal; 0.4 kcal/g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No beverage control condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Liquid orange juice (180 kcal)
Number of subjects: 38
Study: 16707864

Group type: EXPERIMENTAL
Intervention: 1% chloramine solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% formalin solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.02% thymol solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: ‐20 degrees C (no storage solution)
Number of subjects: 40
Study: 15001599

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11139410

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Social Behaviour and Network Therapy (SBNT)
Number of subjects: 720
Study: 9232133

Group type: EXPERIMENTAL
Intervention: Remifentanil, 1 microgram/kg, given over 30 s followed by a continuous infusion of 0.1 microgram.kg‐1.min‐1
Number of subjects: 159

Group type: COMPARATOR
Intervention: Remifentanil+midazolam, 0.5 microgram/kg, given over 30 s followed by a continuous infusion of 0.05 microgram.kg‐1.min‐1
Number of subjects: 159

Group type: COMPARATOR
Intervention: Remifentanil+midazolam
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 159
Study: 8489539

Group type: COMPARATOR
Intervention: Auranofin (AUR)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 281
Study: 3694018

Group type: EXPERIMENTAL
Intervention: Different follow-up groups with intervals of colorectal examination varying from 6 to 48 months after initial polypectomy
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Follow-up programme
Number of subjects: 552

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 552
Study: 29084479

Group type: COMPARATOR
Intervention: Classic laparoscopic dismembered pyeloplasty (Group I)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Laparoscopic in situ dismembered pyeloplasty (Group II)
Number of subjects: 37
Study: 27721212

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 76
Study: 25509703

Group type: EXPERIMENTAL
Intervention: Spherical toric IOL, Acrys of SN60T (Group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aspheric toric IOL, Acrts of SN6AT (Group B)
Number of subjects: 44
Study: 22257673

Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab
Number of subjects: 455

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 455

Group type: COMPARATOR
Intervention: Lapatinib
Number of subjects: 455
Study: 20332728

Group type: EXPERIMENTAL
Intervention: Combined exercises program (COM) group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined exercises program plus jumping (COMpJ) group
Number of subjects: 66
Study: 18248646

Group type: EXPERIMENTAL
Intervention: Staged diabetes management (SDM) strategy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 193
Study: 16154442

Group type: EXPERIMENTAL
Intervention: 24-hour continuous intralipid infusion (20%, 0.4 mg mL(‐1) h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 40
Study: 12949284

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 23
Study: 10895854

Group type: EXPERIMENTAL
Intervention: Pinitol 20 mg x kg(‐1) x day(‐1) (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study: 8797646

Group type: EXPERIMENTAL
Intervention: 5-cm J-pouch (5-J group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10-cm J-pouch (10-J group)
Number of subjects: 40
Study: 1622179

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg every 24 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg every 12 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of Fleroxacin and Ciprofloxacin
Number of subjects: 12
Study: 6541251

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study: 30600794

Group type: EXPERIMENTAL
Intervention: Meaning and Purpose (MaP) therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 57
Study: 29129894

Group type: EXPERIMENTAL
Intervention: Personalized daughter-directed reminder leaflet for cervical cancer screening.
Number of subjects: 2548

Group type: COMPARATOR
Intervention: Combination package containing a personalized daughter-directed reminder leaflet and an additional informational leaflet for the mother requesting her recommendation for screening.
Number of subjects: 2548
Study: 26897630

Group type: EXPERIMENTAL
Intervention: Condolence letter sent 15 days after death
Number of subjects: 264

Group type: COMPARATOR
Intervention: No condolence letter (control)
Number of subjects: 264
Study: 25213203

Group type: EXPERIMENTAL
Intervention: Early post-exercise imaging (Stress-1)
Number of subjects: 229
Study: 22330025

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (9-15 min, frequency = 20-30 Hz, amplitude = 0.44-0.60 mm)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Leg exercises without vibration (control group)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy
Number of subjects: 82
Study: 19265567

Group type: EXPERIMENTAL
Intervention: Compulsory community treatment orders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parliament's responsibility
Number of subjects: 0
Study: 17632305

Group type: EXPERIMENTAL
Intervention: Warm compress (44.4‐45 degrees C) applied for 30 min to the closed eyelids of the experimental eye
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Warm compress protocol repeated to investigate the Fischer‐Schweitzer polygonal reflex
Number of subjects: 24
Study: 15376806

Group type: EXPERIMENTAL
Intervention: Teaching predictive values of features (central or peripheral) for biological properties of animals
Number of subjects: 0
Study: 11400949

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate, 880 microg every 12 hours for 12 weeks from the start date of their CPB conditioning regimen.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Historical control group of 45 consecutive breast cancer patients undergoing ASCT with CPB as a conditioning regimen.
Number of subjects: 63
Study: 9744697

Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual glyceryl trinitrate (GTN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7756937

Group type: EXPERIMENTAL
Intervention: Instrumentation Laboratories reagent
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manchester low-opacity reagent
Number of subjects: 40
Study: 3164051

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study: 28420282

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 32
Study: 26413933

Group type: EXPERIMENTAL
Intervention: Fever control
Number of subjects: 135

Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (MTH)
Number of subjects: 135
Study: 25536598

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with h-R3
Number of subjects: 35

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 35
Study: 23525426

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 66
Study: 20427917

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) - 50 Hz, pulse width 0.5 mSec, intensity 0‐60 mA for 20 minutes for a period of seven days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Microcurrent electrical nerve stimulation (MENS) - 0.5 Hz, intensity 1,000 muA for 20 minutes for a period of seven days
Number of subjects: 60
Study: 18722631

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: All Tadalafil doses
Number of subjects: 1058
Study: 15778231

Group type: EXPERIMENTAL
Intervention: Standard treatment plus stabilising exercises
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 386
Study: 12870339

Group type: EXPERIMENTAL
Intervention: Hunan aqueous drainage (HAD) implantation with mitomycin C (MMC) (0.4 mg/ml, 1 to 5 mins)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Hunan aqueous drainage (HAD) implantation without mitomycin C (MMC)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: HAD implantation with MMC
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: HAD implantation
Number of subjects: 154
Study: 10572768

Group type: EXPERIMENTAL
Intervention: Pain Tracker
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no Pain Tracker)
Number of subjects: 79
Study: 8757659

Group type: EXPERIMENTAL
Intervention: Automatic beam quality selection (OPDOSE) with 26 kVp and a tungsten target with rhodium filtration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manually selected tube potentials with a molybdenum/molybdenum target filter combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automatic beam quality selection (OPDOSE)
Number of subjects: 0
Study: 1820893

Group type: EXPERIMENTAL
Intervention: Pyrimethamine 50mg
Number of subjects: 12
Study: 7129748

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusions over a two-year period
Number of subjects: 1

Group type: COMPARATOR
Intervention: Single-blind placebo infusion
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusions
Number of subjects: 1
Study: 30696812

Group type: EXPERIMENTAL
Intervention: Variants in the ADGRL3 (LPHN3) gene
Number of subjects: 2698

Group type: EXPERIMENTAL
Intervention: rs4860437 variant
Number of subjects: 2698

Group type: EXPERIMENTAL
Intervention: Genetic models
Number of subjects: 2698
Study: 28942805

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Children (DBT-C)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 43
Study: 26424477

Group type: EXPERIMENTAL
Intervention: Formula milk with an ω‐6/ω‐3 ratio of 2/1 (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Formula milk with an ω‐6/ω‐3 ratio of 1/1 (Group B)
Number of subjects: 45
Study: 23013235

Group type: EXPERIMENTAL
Intervention: Academic information condition
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Health information condition
Number of subjects: 721

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 721
Study: 21931861

Group type: EXPERIMENTAL
Intervention: MEMA kwa Vijana adolescent sexual and reproductive health intervention
Number of subjects: 13814

Group type: COMPARATOR
Intervention: Comparison schools (control)
Number of subjects: 13814
Study: 19525833

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (20 sessions, 5 times per week for 4 weeks in a swimming pool at 33 degrees C)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Land-based exercise (home-based exercise, demonstrated by a physiotherapist once with written advice)
Number of subjects: 65
Study: 15834219

Group type: EXPERIMENTAL
Intervention: Low-dose alcoholic beverage (0.4 g/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-dose alcoholic beverage (0.8 g/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (1% ethanol as a taste mask)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alcohol (both doses)
Number of subjects: 16
Study: 12867885

Group type: EXPERIMENTAL
Intervention: Group 1 with PAD
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group 0 without PAD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Presence of albuminuria and retinopathy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Resistive index (RI)
Number of subjects: 150
Study: 10862538

Group type: EXPERIMENTAL
Intervention: OCCL for 3 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-OCCL
Number of subjects: 9
Study: 8880362

Group type: EXPERIMENTAL
Intervention: Simulating amnesia (n = 12 and n = 15)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group not simulating amnesia (n = 14)
Number of subjects: 41
Study: 1907056

Group type: EXPERIMENTAL
Intervention: Diltiazem (90-360 mg per day based on body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6322505

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/day for 3 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg/day for 6 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Miconazole 100 mg/day for 14 days
Number of subjects: 140
Study: 31604631

Group type: EXPERIMENTAL
Intervention: Dosing cups
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Oral syringes
Number of subjects: 493
Study: 28274772

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily for 5 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 25690774

Group type: EXPERIMENTAL
Intervention: Gans repositioning maneuver with postmaneuver restrictions (GRMR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gans repositioning maneuver (GRM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Canalith repositioning maneuver (CRM)
Number of subjects: 45
Study: 24284414

Group type: EXPERIMENTAL
Intervention: Once daily mesalazine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Three times daily mesalazine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: General adherence measures
Number of subjects: 58
Study: 22682806

Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gem) treatment arm with CA 19-9 <90 U/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gem) treatment arm with CA 19-9 ≥90 U/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gem) treatment arm with RT quality assurance per protocol and CA 19-9 <90 U/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine (Gem) arm of the CONKO trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA 19-9 serum level ≥90 U/mL
Number of subjects: 0
Study: 19125777

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 2789

Group type: COMPARATOR
Intervention: Glimepiride (titrated up to 6 mg/day, mean dose 4.5 mg/day)
Number of subjects: 2789
Study: 17381394

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g qd)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (3.375 g q6h)
Number of subjects: 494
Study: 15978925

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1082
Study: 12699137

Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure (HBP) measurement
Number of subjects: 362

Group type: COMPARATOR
Intervention: Clinic blood pressure (CBP) measurement
Number of subjects: 362
Study: 10402160

Group type: EXPERIMENTAL
Intervention: Thrice‐weekly buprenorphine dose schedules (64, 84, and 112 mg weekly)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily buprenorphine dose of 16 mg/70 kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thrice‐weekly buprenorphine dose schedules
Number of subjects: 10
Study: 8684155

Group type: EXPERIMENTAL
Intervention: Hyperventilation provocation test (HVPT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo test (isocapnic overbreathing)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ambulatory transcutaneous monitoring of pCO2
Number of subjects: 115
Study: 1745842

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 94
Study: 12265803

Group type: EXPERIMENTAL
Intervention: ML Cu 250-standard
Number of subjects: 375

Group type: COMPARATOR
Intervention: ML Cu 250-short
Number of subjects: 375
Study: 30168408

Group type: EXPERIMENTAL
Intervention: Memory strategy training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control memory training
Number of subjects: 60
Study: 27783532

Group type: EXPERIMENTAL
Intervention: Sildenafil thermosensitive vaginal gel
Number of subjects: 0
Study: 26265452

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation intervention (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham transcranial magnetic stimulation intervention (n = 30)
Number of subjects: 60
Study: 24327037

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 194
Study: 21251653

Group type: EXPERIMENTAL
Intervention: LMWH (enoxaparin 40 mg, once daily) plus LDA
Number of subjects: 60

Group type: COMPARATOR
Intervention: UFH (5000 units, twice daily) plus LDA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LMWH plus LDA
Number of subjects: 60

Group type: COMPARATOR
Intervention: UFH plus LDA
Number of subjects: 60
Study: 18482635

Group type: EXPERIMENTAL
Intervention: Highly visible CPP display
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (without additional CPP display)
Number of subjects: 100
Study: 16253973

Group type: EXPERIMENTAL
Intervention: Elective single embryo transfer (eSET)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Standard policy for eSET (SP-eSET)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard policy for double embryo transfer (SP-DET)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard policy for eSET and DET
Number of subjects: 308
Study: 12705778

Group type: EXPERIMENTAL
Intervention: TEOAEs in elderly subjects (n=45)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group of normal-hearing young adults (n=20)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: TEOAEs presence in left ears
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Subjects with PTA above 40 dB HL
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Subgroup with TEOAEs
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Overall response level and overall reproducibility
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Average hearing level
Number of subjects: 232
Study: 10749603

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (5-FU) administered at 0.6 g/m2/day for 6 days (day 4 to day 10) plus intravenous 5-FU (1 g) during surgery
Number of subjects: 267

Group type: COMPARATOR
Intervention: Resection alone (Control group)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-FU (full treatment)
Number of subjects: 267
Study: 9361576

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (n = 32)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Loratadine (n = 33)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (n = 33)
Number of subjects: 98
Study: 1525128

Group type: EXPERIMENTAL
Intervention: 60% phosphoric acid gel with 0.5% NaF (Orthoprep) for 5 seconds
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Orthoprep for 15 seconds
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Orthoprep for 30 seconds
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Orthoprep for 60 seconds
Number of subjects: 75

Group type: COMPARATOR
Intervention: 37% non‐fluoridated phosphoric acid gel (Coe) for 60 seconds
Number of subjects: 75
Study: 2865027

Group type: EXPERIMENTAL
Intervention: Dezocine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29431455

Group type: EXPERIMENTAL
Intervention: 90-minute Prolonged Exposure therapy sessions
Number of subjects: 160

Group type: COMPARATOR
Intervention: 60-minute Prolonged Exposure therapy sessions
Number of subjects: 160
Study: 28323164

Group type: EXPERIMENTAL
Intervention: Caffeine (250mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25858265

Group type: EXPERIMENTAL
Intervention: Disease activity guided dose reduction of adalimumab or etanercept
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study: 23298304

Group type: EXPERIMENTAL
Intervention: Transanal, submucosal injection of 4 x 1 mL of dextranomer in hyaluronic acid
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sphincter training with biofeedback
Number of subjects: 126

Group type: COMPARATOR
Intervention: Comparison of St Mark's scores between the groups
Number of subjects: 126
Study: 22182346

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 34
Study: 19248862

Group type: EXPERIMENTAL
Intervention: Low-fat/low-glycemic load diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard American diet
Number of subjects: 8
Study: 16705845

Group type: EXPERIMENTAL
Intervention: Jinger moxibustion
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 78